Renard V, Romero P, Vivier E, Malissen B, Luescher I F
Centre d'Immunologie Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique de Marseille-Luminy, France.
J Exp Med. 1996 Dec 1;184(6):2439-44. doi: 10.1084/jem.184.6.2439.
To study the role of CD8 beta in T cell function, we derived a CD8 alpha/beta-(CD8-/-) T cell hybridoma of the H-2Kd-restricted N9 cytotoxic T lymphocyte clone specific for a photoreactive derivative of the Plasmodium berghei circumsporozoite peptide PbCS 252-260. This hybridoma was transfected either with CD8 alpha alone or together with CD8 beta. All three hybridomas released interleukin 2 upon incubation with L cells expressing Kd-peptide derivative complexes, though CD8 alpha/beta cells did so more efficiently than CD8 alpha/alpha and especially CD8-/- cells. More strikingly, only CD8 alpha/beta cells were able to recognize a weak agonist peptide derivative variant. This recognition was abolished by Fab' fragments of the anti-Kd alpha 3 monoclonal antibody SF1-1.1.1 or substitution of Kd D-227 with K, both conditions known to impair CD8 coreceptor function. T cell receptor (TCR) photoaffinity labeling indicated that TCR-ligand binding on CD8 alpha/beta cells was approximately 5- and 20-fold more avid than on CD8 alpha/a and CD8-/- cells, respectively. SF1-1.1.1 Fab' or Kd mutation D227K reduced the TCR photoaffinity labeling on CD8 alpha/beta cells to approximately the same low levels observed on CD8-/- cells. These results indicate that CD8 alpha/beta is a more efficient coreceptor than CD8alpha/alpha, because it more avidly strengthens TCR-ligand binding.
为了研究CD8β在T细胞功能中的作用,我们从H-2Kd限制性N9细胞毒性T淋巴细胞克隆中获得了一种CD8α/β -(CD8 - / -)T细胞杂交瘤,该克隆对伯氏疟原虫环子孢子蛋白肽PbCS 252 - 260的光反应性衍生物具有特异性。该杂交瘤分别用单独的CD8α或与CD8β一起转染。所有三种杂交瘤在与表达Kd - 肽衍生物复合物的L细胞孵育时都会释放白细胞介素2,尽管CD8α/β细胞比CD8α/α细胞,尤其是CD8 - / -细胞更有效地释放。更引人注目的是,只有CD8α/β细胞能够识别一种弱激动剂肽衍生物变体。这种识别被抗Kdα3单克隆抗体SF1 - 1.1.1的Fab'片段或用K取代Kd D - 227所消除,这两种情况都已知会损害CD8共受体功能。T细胞受体(TCR)光亲和标记表明,TCR - 配体在CD8α/β细胞上的结合亲和力分别比在CD8α/α和CD8 - / -细胞上高约5倍和20倍。SF1 - 1.1.1 Fab'或Kd突变D227K将CD8α/β细胞上的TCR光亲和标记降低到与CD8 - / -细胞上观察到的大致相同的低水平。这些结果表明,CD8α/β是比CD8α/α更有效的共受体,因为它能更强烈地增强TCR - 配体结合。